ReportWire

Tag: Novo Nordisk AS

  • Another rally for Alphabet leads the US stock market higher

    [ad_1]

    NEW YORK (AP) — The U.S. stock market rallied on Monday, at the start of a week with shortened trading because of the Thanksgiving holiday.

    The S&P 500 climbed 1.5% for one of its best days since the summer and added to its jump from Friday, finding some strength following a shaky few weeks. The Dow Jones Industrial Average rose 202 points, or 0.4%, and the Nasdaq composite jumped 2.7%.

    Stocks got a lift from rising hopes that the Federal Reserve will cut its main interest rate again at its next meeting in December, a move that could boost the economy and investment prices.

    The market also benefited from strength for stocks caught up in the artificial-intelligence frenzy. Alphabet, which has been getting praise for its newest Gemini AI model, rallied 6.3% and was one of the strongest forces lifting the S&P 500. Nvidia rose 2.1%.

    Monday’s gains followed sharp swings in recent weeks, not just day to day but also hour to hour, caused by uncertainty about what the Fed will do with interest rates and whether too much money is pouring into AI and creating a bubble. All the worries are creating the biggest test for investors since an April sell-off, when President Donald Trump shocked the world with his “Liberation Day” tariffs.

    Despite all the recent fear, the S&P 500 remains within 2.7% of its record set last month.

    “It’s reasonable to expect that stocks will experience periods of pressure from time to time, which, historically, is quite healthy for longer-term strength,” Anthony Saglimbene, Ameriprise chief market strategist, wrote in a note to investors.

    Several more tests lie ahead this week for the market, which could create more swings, though none loom quite as large as last week’s profit report from Nvidia or the delayed jobs report from the U.S. government for September.

    One of the biggest tests will arrive Tuesday, when the U.S. government will deliver data showing how bad inflation was at the wholesale level in September.

    Economists expect it to show a 2.6% rise in prices from a year earlier, the same inflation rate as August. A worse-than-expected reading could deter the Fed from cutting its main interest rate in December for a third time this year, because lower rates can worsen inflation. Some Fed officials have already argued against a December cut in part because inflation has stubbornly remained above their 2% target.

    Traders are nevertheless betting on a nearly 85% probability that the Fed will cut rates next month, up from 71% on Friday and from less than a coin flip’s chance seen a week ago, according to data from CME Group.

    U.S. markets will be closed on Thursday for the Thanksgiving holiday. A day later, it’s on to the rush of Black Friday and Cyber Monday.

    On Wall Street, U.S.-listed shares of Danish drugmaker Novo Nordisk fell 5.6% Monday after it reported that its Alzheimer’s drug failed to slow progression of the disease in a trial.

    Grindr dropped 12.1% after saying it’s breaking off talks with a couple of investors who had offered to buy the company, which helps its gay users connect with each other. A special committee of the company’s board of directors said it had questions about the financing for the deal by the investors, who collectively own more than 60% of Grindr’s stock.

    All told, the S&P 500 rose 102.13 points to 6,705.12. The Dow Jones Industrial Average climbed 202.86 to 46,448.27, and the Nasdaq composite jumped 598.92 to 22,872.01.

    Bitcoin, meanwhile, continued it sharp swings. It was sitting around $89,000 after bouncing between $82,000 and $94,000 over the last week. It was near $125,000 last month.

    In stock markets abroad, indexes were mixed in Europe and Asia.

    Hong Kong’s Hang Seng jumped 2% for one of the world’s biggest moves. It got a boost from a 4.7% leap for Alibaba, which has reported strong demand for its updated Qwen AI app. Alibaba is due to report earnings on Tuesday.

    In the bond market, Treasury yields eased a bit. The yield on the 10-year Treasury fell to 4.03% from 4.06% late Friday.

    ___

    AP Business Writers Matt Ott and Elaine Kurtenbach contributed.

    [ad_2]

    Source link

  • Layoffs are piling up, raising worker anxiety. Here are some companies that have cut jobs recently

    [ad_1]

    NEW YORK (AP) — It’s a tough time to be looking for a job.

    Amid wider economic uncertainty, some analysts have said that businesses are at a “no-hire, no fire” standstill. That’s caused many to limit new work to only a few specific roles, if not pause openings entirely. At the same time, sizable layoffs have continued to pile up — raising worker anxieties across sectors.

    Some companies have pointed to rising operational costs spanning from President Donald Trump’s barrage of new tariffs and shifts in consumer spending. Others cite corporate restructuring more broadly — or, as seen with big names like Amazon, are redirecting money to artificial intelligence.

    Federal employees have encountered additional doses of uncertainty, impacting worker sentiment around the job market overall. Shortly after Trump returned to office at the start of the year, federal jobs were cut by the thousands. And the record 43-day government shutdown also left many to work without paychecks.

    The impasse put key economic data on hold, too. In a delayed report released Thursday, the Labor Department said U.S. employers added a surprising 119,000 jobs in September. But unemployment rose to 4.4% — and other troubling details emerged, including revisions showing the economy actually lost 4,000 jobs in August. There’s also growing gender and racial disparities. The National Women’s Law Center notes women only accounted for 21,000 of September’s added jobs — and that Black women over the age of 20, in particular, saw unemployment climb to 7.5% for the month.

    The shutdown has left holes in more recent hiring numbers. The government says it won’t release a full jobs report for October.

    Here are some of the largest job cuts announced recently:

    Verizon

    In November, Verizon began laying off more than 13,000 employees. In a staff memo announcing the cuts, CEO Dan Schulman said that the telecommunications giant needed to simplify operations and “reorient” the entire company.

    General Motors

    General Motors moved to lay off about 1,700 workers across manufacturing sites in Michigan and Ohio in late October, as the auto giant adjusts to slowing demand for electric vehicles. Hundreds of additional employees are reportedly slated for “temporary layoffs” at the start of next year.

    Paramount

    In long-awaited cuts just months after completing its $8 billion merger with Skydance, Paramount plans to lay off about 2,000 employees — about 10% of its workforce. Paramount initiated roughly 1,000 of those layoffs in late October, according to a source familiar with the matter.

    In November, Paramount also announced plans to eliminate 1,600 positions as part of divestitures of Televisión Federal in Argentina and Chilevision in Chile. And the company said another 600 employees had chosen voluntary severance packages as part of a coming push to return to the office full-time.

    Amazon

    Amazon said last month that it will cut about 14,000 corporate jobs, close to 4% of its workforce, as the online retail giant ramps up spending on AI while trimming costs elsewhere. A letter to employees said most workers would be given 90 days to look for a new position internally.

    UPS

    United Parcel Service has disclosed about 48,000 job cuts this year as part of turnaround efforts, which arrive amid wider shifts in the company’s shipping outputs. UPS also closed daily operations at 93 leased and owned buildings during the first nine months of this year.

    Target

    Target in October moved to eliminate about 1,800 corporate positions, or about 8% of its corporate workforce globally. The retailer said the cuts were part of wider streamlining efforts.

    Nestlé

    In mid-October, Nestlé said it would be cutting 16,000 jobs globally — as part of wider cost cutting aimed at reviving its financial performance amid headwinds like rising commodity costs and U.S. imposed tariffs. The Swiss food giant said the layoffs would take place over the next two years.

    Lufthansa Group

    In September, Lufthansa Group said it would shed 4,000 jobs by 2030 — pointing to the adoption of artificial intelligence, digitalization and consolidating work among member airlines.

    Novo Nordisk

    Also in September, Danish pharmaceutical company Novo Nordisk said it would cut 9,000 jobs, about 11% of its workforce. The company — which makes drugs like Ozempic and Wegovy — said the layoffs were part of wider restructuring, as it works to sell more obesity and diabetes medications amid rising competition.

    ConocoPhillips

    Oil giant ConocoPhillips announced plans in September to lay off up to a quarter of its workforce, as part of broader efforts from the company to cut costs. Between 2,600 and 3,250 workers were expected to be impacted, with most layoffs set to take place before the end of 2025.

    Intel

    Intel has moved to shed thousands of jobs — with the struggling chipmaker working to revive its business. In July, CEO Lip-Bu Tan said Intel expected to end the year with 75,000 “core” workers, excluding subsidiaries, through layoffs and attrition. That’s down from 99,500 core employees reported the end of last year. The company previously announced a 15% workforce reduction.

    Microsoft

    In May, Microsoft began laying off about 6,000 workers across its workforce. And just months later, the tech giant said it would be cutting 9,000 positions — marking its biggest round of layoffs seen in more than two years. The company has cited “organizational changes,” but the labor reductions also arrive as the company spends heavily on AI.

    Procter & Gamble

    In June, Procter & Gamble said it would cut up to 7,000 jobs over the next two years, 6% of the company’s global workforce. The maker of Tide detergent and Pampers diapers said the cuts were part of a wider restructuring — also arriving amid tariff pressures.

    [ad_2]

    Source link

  • Novo cuts Wegovy prices, but doctors still see cost challenges for patients

    [ad_1]

    Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance.

    The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to patients paying the full bill. That’s down from $499, and in line with terms of a drug pricing agreement outlined earlier this month by President Donald Trump’s administration.

    Novo also started a temporary offer of $199 a month for the first two months of low doses of Wegovy and the drug’s counterpart for diabetes, Ozempic. The new pricing will be available at pharmacies nationwide, through home delivery and from some telemedicine providers.

    Rival Eli Lilly also plans price breaks for its weight-loss drug Zepbound once it gets a new, multi-dose pen on the market. Lilly has said it will sell a starter dose of Zepbound for $299 a month and additional doses at up to $449. Both represent $50 reductions from current prices for sales directly to patients.

    Obesity treatments like Zepbound and Wegovy have soared in popularity in recent years. Known as GLP-1 receptor agonists, the drugs work by targeting hormones in the gut and brain that affect appetite and feelings of fullness.

    In clinical trials, they helped people shed 15% to 22% of their body weight — up to 50 pounds or more in many cases. But affordability has been a persistent challenge for patients.

    A recent poll by the nonprofit KFF found that about half of the people who take the treatments say it was hard to afford them.

    Both Lilly and Novo announced price cuts earlier this year that brought the cost of higher doses of their treatments down to around $500 a month.

    Previous research has shown that people have difficulty paying for a medication when the cost rises above $100 per month, said Stacie Dusetzina, a Vanderbilt University Medical Center professor and prescription drug pricing expert.

    She said Novo’s new prices are “not going to really move the needle for a person who doesn’t have a pretty reasonable amount of disposable income.”

    Dr. Laura Davisson said the medication would still be unaffordable for patients on Medicaid in states where the government-funded program for people with low incomes doesn’t cover the drug.

    The bigger issue is expanding coverage of the treatments, said Davisson, a West Virginia University obesity specialist.

    “We’ve had hundreds of people lose coverage over the last couple of years, and we keep seeing more and more insurers drop coverage,” she said, adding that her practice has started a group support program to help those who have lost coverage.

    Coverage is slated to improve starting next year for at least one big payer under a deal announced by the Trump administration. The federally funded Medicare program, mainly for people ages 65 and older, will begin covering the treatments for people who have severe obesity and others who are overweight or obese and have serious health problems.

    Those who qualify will pay $50 copays for the medicine.

    Administration officials also said lower prices for the drugs that they negotiated for Medicare also will be provided for Medicaid programs.

    That will help expand coverage, according to Dave Moore, Novo’s executive vice president for U.S. operations. He said Medicaid programs in 20 states cover the drug for obesity.

    Novo officials expect around 40 million more Americans will gain access to their drug through coverage expansions for Medicaid and Medicare.

    Neither Moore nor representatives for Eli Lilly would say whether they plan additional price cuts. Both companies also are seeking approval of pill versions of the drugs, which would come with new prices.

    Lilly spokesperson Courtney Kasinger said the company believes obesity treatments should be covered just like those for any other chronic condition.

    “We’re going to continue to work to improve coverage as much as we can across all channels, all stakeholders,” she said.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • Trump is ramping up a new effort to convince a skeptical public he can fix affordability worries

    [ad_1]

    WASHINGTON (AP) — President Donald Trump is adjusting his messaging strategy to win over voters who are worried about the cost of living with plans to emphasize new tax breaks and show progress on fighting inflation.

    The messaging is centered around affordability, and the push comes after inflation emerged as a major vulnerability for Trump and Republicans in Tuesday’s elections, in which voters overwhelmingly said the economy was their biggest concern.

    Democrats took advantage of concerns about affordability to run up huge margins in the New Jersey and Virginia governor races, flipping what had been a strength for Trump in the 2024 presidential election into a vulnerability going into next year’s midterm elections.

    White House officials and others familiar with their thinking requested anonymity to speak for this article in order to not get ahead of the president’s actions. They stressed that affordability has always been a priority for Trump, but the president plans to talk about it more, as he did Thursday when he announced that Eli Lilly and Novo Nordisk would reduce the price of their anti-obesity drugs.

    “We are the ones that have done a great job on affordability, not the Democrats,” Trump said at an event in the Oval Office to announce the deal. “We just lost an election, they said, based on affordability. It’s a con job by the Democrats.”

    The White House is keeping up a steady drumbeat of posts on social media about prices and deals for Thanksgiving dinner staples at retailers such as Walmart, Lidl, Aldi and Target.

    “I don’t want to hear about the affordability, because right now, we’re much less,” Trump told reporters Thursday, arguing that things are much better for Americans with his party in charge.

    “The only problem is the Republicans don’t talk about it,” he said.

    The outlook for inflation is unclear

    As of now, the inflation outlook has worsened under Trump. Consumer prices in September increased at an annual rate of 3%, up from 2.3% in April, when the president first began to roll out substantial tariff hikes that suddenly burdened the economy with uncertainty. The AP Voter Poll showed the economy was the leading issue in Tuesday’s elections in New Jersey, Virginia, New York City and California.

    Grocery prices continue to climb, and recently, electricity bills have emerged as a new worry. At the same time, the pace of job gains has slowed, plunging 23% from the pace a year ago.

    The White House maintains a list of talking points about the economy, noting that the stock market has hit record highs multiple times and that the president is attracting foreign investment. Trump has emphasized that gasoline prices are coming down, and maintained that gasoline is averaging $2 a gallon, but AAA reported Thursday that the national average was $3.08, about two cents lower than a year ago.

    “Americans are paying less for essentials like gas and eggs, and today the Administration inked yet another drug pricing deal to deliver unprecedented health care savings for everyday Americans,” said White House spokesman Kush Desai.

    Trump gets briefed about the economy by Treasury Secretary Scott Bessent and other officials at least once a week and there are often daily discussions on tariffs, a senior White House official said, noting Trump is expected to do more domestic travel next year to make his case that he’s fixing affordability.

    But critics say it will be hard for Trump to turn around public perceptions on affordability.

    “He’s in real trouble and I think it’s bigger than just cost of living,” said Lindsay Owens, executive director of Groundwork Collaborative, a liberal economic advocacy group.

    Owens noted that Trump has “lost his strength” as voters are increasingly doubtful about Trump’s economic leadership compared to Democrats, adding that the president doesn’t have the time to turn around public perceptions of him as he continues to pursue broad tariffs.

    New hype about income tax cuts ahead of April

    There will be new policies rolled out on affordability, a person familiar with the White House thinking said, declining to comment on what those would be. Trump on Thursday indicated there will be more deals coming on drug prices. Two other White House officials said messaging would change — but not policy.

    A big part of the administration’s response on affordability will be educating people ahead of tax season about the role of Trump’s income tax cuts in any refunds they receive in April, the person familiar with planning said. Those cuts were part of the sprawling bill Republicans muscled through Congress in July.

    This individual stressed that the key challenge is bringing prices down while simultaneously having wages increase, so that people can feel and see any progress.

    There’s also a bet that the economy will be in a healthier place in six months. With Federal Reserve Chair Jerome Powell’s term ending in May, the White House anticipates the start of consistent cuts to the Fed’s benchmark interest rate. They expect inflation rates to cool and declines in the federal budget deficit to boost sentiment in the financial markets.

    But the U.S. economy seldom cooperates with a president’s intentions, a lesson learned most recently by Trump’s predecessor, Democrat Joe Biden, who saw his popularity slump after inflation spiked to a four-decade high in June 2022.

    The Trump administration maintains it’s simply working through an inflation challenge inherited from Biden, but new economic research indicates Trump has created his own inflation challenge through tariffs.

    Since April, Harvard University economist Alberto Cavallo and his colleagues, Northwestern University’s Paola Llamas and Universidad de San Andres’ Franco Vazquez, have been tracking the impact of the import taxes on consumer prices.

    In an October paper, the economists found that the inflation rate would have been drastically lower at 2.2%, had it not been for Trump’s tariffs.

    The administration maintains that tariffs have not contributed to inflation. They plan to make the case that the import taxes are helping the economy and dismiss criticisms of the import taxes as contributing to inflation as Democratic talking points.

    The fate of Trump’s country-by-country tariffs is currently being decided by the Supreme Court, where justices at a Wednesday hearing seemed dubious over the administration’s claims that tariffs were essentially regulations and could be levied by a president without congressional approval. Trump has maintained at times that foreign countries pay the tariffs and not U.S. citizens, a claim he backed away from slightly Thursday.

    “They might be paying something,” he said. “But when you take the overall impact, the Americans are gaining tremendously.”

    _____

    Associated Press writers Will Weissert and Michelle L. Price contributed to this report.

    [ad_2]

    Source link

  • Trump unveils deal to expand coverage and lower costs on obesity drugs

    [ad_1]

    WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy.

    Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years, but patient access has been a consistent problem because of their cost — around $500 a month for higher doses — and insurance coverage has been spotty. More than 100 million American adults are obese, according to federal estimates.

    Coverage of the drugs for obesity will expand to Medicare patients starting next year, according to the administration, which said some lower prices also will be phased in for patients without coverage. Starting doses of new, pill versions of the treatments also will cost $149 a month if they are approved.

    “(It) will save lives, improve the health of millions and millions of Americans,” said Trump, in an Oval Office announcement in which he referred to GLP-1s as a “fat drug.”

    Thursday’s announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters. Pfizer and AstraZeneca recently agreed to lower the cost of prescription drugs for Medicaid after an executive order in May set a deadline for drugmakers to electively lower prices or face new limits on what the government will pay.

    As with the other deals, it’s not clear how much the price drop will be felt by consumers. Drug prices can vary based on the competition for treatments and insurance coverage.

    Obesity drugs are popular, but costly

    The obesity drugs work by targeting hormones in the gut and brain that affect appetite and feelings of fullness. In clinical trials, they helped people shed 15% to 22% of their body weight — up to 50 pounds or more in many cases.

    Patients usually start on smaller doses and then work up to larger amounts, depending on their needs. They need to stay on the the treatments indefinitely or risk regaining weight, experts say.

    The medications have proven especially lucrative for Lilly and Novo. Lilly said recently that sales of Zepbound have tripled so far this year to more than $9 billion.

    But for many Americans, their cost has made them out of reach.

    Medicare, the federally funded coverage program mainly for people ages 65 and over, now covers the cost of the drugs for conditions such as type 2 diabetes and cardiovascular disease, but not for weight loss alone. Trump’s predecessor, Joe Biden, proposed a rule last November that would have changed that, but the Trump administration nixed it.

    Few state and federally funded Medicaid programs, for people with low incomes, offer coverage. And employers and insurers that provide commercial coverage are wary of paying for these drugs in part because so many people might use them.

    The $500 monthly price for higher doses of the treatments also makes them unaffordable for those without insurance, doctors say.

    Trump tries to show he is in touch with cost-of-living concerns

    Thursday’s announcement comes as the White House is looking to demonstrate that Trump is in touch with Americans’ frustrations with rising costs for food, housing, health care and other necessities.

    “Trump is the friend of the forgotten American,” said Health and Human Services Secretary Robert F. Kennedy, Jr. at Thursday’s announcement. “Obesity is a disease of poverty. And overwhelmingly, these drugs have only been available for people who have wealth.”

    (Obesity rates actually are slightly higher for middle-income Americans than they are for those with the lowest and highest incomes, according to 2017-2020 data collected by the U.S. Centers for Disease Control and Prevention.)

    Kennedy had previously expressed skepticism about GLP-1s, but he was full of praise for Trump for pushing to help a broader segment of Americans have access to the drug.

    Trump, who has a history of commenting on people’s appearance, asked the officials who joined him in the Oval Office whether they had used the weight-loss medications.

    “Do you take any of this stuff, Howard?” Trump asked Commerce Secretary Howard Lutnick. “Not yet,” Lutnick replied. “He’s taking it,” the president said of Steven Cheung, who is the White House director of communications.

    The drug-pricing announcement came days after Democrats swept elections in races across the country. Economic worries were the dominant concern for those casting their ballots, according to findings from the AP voter poll.

    Plan calls for phased-in price reductions

    The White House sought to diminish price-reduction efforts by the previous Democratic administration as a gift to the pharmaceutical industry.

    Trump, instead, consummated a deal that ensures Americans aren’t unfairly financing the pharmaceutical industry’s innovation, claimed a senior administration official, who briefed reporters ahead of Thursday’s Oval Office announcement.

    Another senior administration official said coverage of the drugs will expand to Medicare patients starting next year. The program will start covering the treatments for people who have severe obesity and others who are overweight or obese and have serious health problems, the official said. Those who qualify will pay $50 copays for the medicine.

    Lower prices also will be phased in for people without coverage through the administration’s TrumpRx program, which will allow people to buy drugs directly from manufacturers, starting in January.

    Administration officials said the average price of the drugs sold on TrumpRx will start at around $350 and then drop to $245 over the next two years.

    A Novo Nordisk spokesperson declined to provide details on their pricing changes.

    Lilly said it will sell a starter dose of Zepbound for $299 a month and additional doses at up to $449. Both represent $50 reductions from current prices for doses it sells directly to patients.

    Administration officials said lower prices also will be provided for state and federally funded Medicaid programs. And starting doses of new, pill versions of the obesity treatments will cost $149 a month if they are approved.

    U.S. health regulators on Thursday separately agreed to dramatically expedite review of Lilly’s obesity pill, orforglipron. An FDA decision on Novo Nordisk’s Wegovy pill is expected later this year.

    Doctors who treat patients for obesity say help is needed to improve access. Dr. Leslie Golden says she has roughly 600 patients taking one of these treatments, and at least 75% struggle to afford them. Even with coverage, some face $150 copayments for refills.

    “Every visit it’s, ‘How long can we continue to do this? What’s the plan if I can’t continue?’” said Golden, an obesity medicine specialist in Watertown, Wisconsin. “Some of them are working additional jobs or delaying retirement so they can continue to pay for it.”

    ___

    AP Health Writer Matthew Perrone contributed to this report.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • Layoffs are piling up, raising worker anxiety. Here are some companies that have cut jobs recently

    [ad_1]

    NEW YORK (AP) — It’s a tough time for the job market.

    Amid wider economic uncertainty, some analysts have said that businesses are at a “no-hire, no fire” standstill. That’s caused many to limit new work to only a few specific roles, if not pause openings entirely. At the same time, some sizeable layoffs have continued to pile up — raising worker anxieties across sectors.

    Some companies have pointed to rising operational costs spanning from President Donald Trump’s barrage of new tariffs and shifts in consumer spending. Others cite corporate restructuring more broadly — or, as seen with big names like Amazon, are redirecting money to artificial intelligence.

    Federal employees have encountered additional doses of uncertainty, impacting worker sentiment around the job market overall. Shortly after Trump returned to office at the start of the year, federal jobs were cut by the thousands. And many workers are now going without pay as the U.S. government shutdown nears its fourth week.

    “A lot of people are looking around, scanning the job environment, scanning the opportunities that are available to them — whether it’s in the public or private sector,” said Jason Schloetzer, professor business administration at Georgetown University’s McDonough School. “And I think there’s a question mark around the long-term stability everywhere.”

    Government hiring data is on hold during the shutdown, but earlier this month a survey by payroll company ADP showed that the private sector lost 32,000 jobs in September.

    Here are some companies that have moved to cut jobs recently.

    General Motors

    General Motors moved to lay off about 1,700 workers across manufacturing sites in Michigan and Ohio on Wednesday, as the auto giant adjusts to slowing demand for electric vehicles.

    Hundreds of additional employees are reportedly slated for “temporary layoffs.” And GM has recently moved to downsize other parts of its workforce, too — including 200 layoffs mostly impacting engineers in Detroit, and other 300 job cuts at a Georgia IT Innovation Center, which it is also shuttering.

    Paramount

    In long-awaited cuts just months after completing its $8 billion merger with Skydance, Paramount is going to lay off about 2,000 employees — about 10% of its workforce.

    Paramount initiated roughly 1,000 of those layoffs on Wednesday, according to a source familiar with the matter, who spoke on the condition of anonymity. The rest of the cuts will be made at a later date.

    Amazon

    Amazon will cut about 14,000 corporate jobs as the online retail giant ramps up spending on artificial intelligence.

    Amazon said Tuesday that it will cut about 14,000 corporate jobs, close to 4% of its workforce, as the online retail giant ramps up spending on AI while trimming costs elsewhere. A letter to employees said most workers would be given 90 days to look for a new position internally.

    CEO Andy Jassy previously said he anticipated generative AI would reduce Amazon’s corporate workforce in the coming years. And he has worked to aggressively cut costs overall since 2021.

    UPS

    United Parcel Service has disclosed about 48,000 job cuts this year as part of turnaround efforts, which arrive amid wider shifts in the company’s shipping outputs.

    In a Tuesday regulatory filing, UPS said it’s cut about 34,000 operational positions — and the company announced another 14,000 role reductions, mostly within management. Combined, that’s much higher than the roughly 20,000 cuts UPS forecast earlier this year.

    Target

    Last week, Target that it would eliminate about 1,800 corporate positions, or about 8% of its corporate workforce globally.

    Target said the cuts were part of wider streamlining efforts — with Chief Operating Officer Michael Fiddelke noting that “too many layers and overlapping work have slowed decisions.” The retailer is also looking to rebuild its customer base. Target reported flat or declining comparable sales in nine of the past eleven quarters.

    Nestlé

    In mid-October, Nestlé said it would be cutting 16,000 jobs globally — as part of wider cost cutting aimed at reviving its financial performance.

    The Swiss food giant said the layoffs would take place over the next two years. The cuts arrive as Nestlé and others face headwinds like rising commodity costs and U.S. imposed tariffs. The company announced price hikes over the summer to offset higher coffee and cocoa costs.

    Lufthansa Group

    In September, Lufthansa Group said it would shed 4,000 jobs by 2030 — pointing to the adoption of artificial intelligence, digitalization and consolidating work among member airlines.

    Most of the lost jobs would be in Germany, and the focus would be on administrative rather than operational roles, the company said. The layoff plans arrived even as the company reported strong demand for air travel and predicted stronger profits in years ahead.

    Novo Nordisk

    Also in September, Danish pharmaceutical company Novo Nordisk said it would cut 9,000 jobs, about 11% of its workforce.

    Novo Nordisk — which makes drugs like Ozempic and Wegovy — said the layoffs were part of wider restructuring as the company works to sell more obesity and diabetes medications amid rising competition.

    ConocoPhillips

    Oil giant ConocoPhillips has said it plans to lay off up to a quarter of its workforce, as part of broader efforts from the company to cut costs.

    A spokesperson for ConocoPhillips confirmed the layoffs on Sept. 3, noting that 20% to 25% of the company’s employees and contractors would be impacted worldwide. At the time, ConocoPhillips had a total headcount of about 13,000 — or between 2,600 and 3,250 workers. Most reductions were expected to take place before the end of 2025.

    Intel

    Intel has moved to shed thousands of jobs — with the struggling chipmaker working to revive its business as it lags behind rivals like Nvidia and Advanced Micro Devices.

    In a July memo to employees, CEO Lip-Bu Tan said Intel expected to end the year with 75,000 “core” workers, excluding subsidiaries, through layoffs and attrition. That’s down from 99,500 core employees reported the end of last year. The company previously announced a 15% workforce reduction.

    Microsoft

    In May, Microsoft began began laying off about 6,000 workers across its workforce. And just months later, the tech giant said it would be cutting 9,000 positions — marking its biggest round of layoffs seen in more than two years.

    The latest job cuts hit Microsoft’s Xbox video game business and other divisions. The company has cited “organizational changes,” with many executives characterizing the layoffs as part of a push to trim management layers. But the labor reductions also arrive as the company spends heavily on AI.

    Procter & Gamble

    In June, Procter & Gamble said it would cut up to 7,000 jobs over the next two years, 6% of the company’s global workforce.

    The maker of Tide detergent and Pampers diapers said the cuts were part of a wider restructuring — also arriving amid tariff pressures. In July, P&G said it would hike prices on about a quarter of its products due to the newly-imposed import taxes, although it’s since said it expects to take less of a hit than previously anticipated for the 2026 fiscal year.

    [ad_2]

    Source link